Michele Simonetti
Research Subjects
Michele Simonetti has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Luuk Harbers
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
8 shared publications - Nicola Crosetto
Human Technopole
8 shared publications - Magda Bienko
Human Technopole
7 shared publications - Ning Zhang
Department of Breast Surgery General Surgery Qilu Hospital of Shandong University Ji'nan China
6 shared publications Anna Sapino
Instituto di Candiolo FPO - IRCCS
4 shared publicationsAntonino Sottile
Instituto di Candiolo FPO - IRCCS
4 shared publications
Latest Publications
- Open Access
Single-Cell Protein Interactomes by the Proximity Network Assay
Cellular function depends on dynamic interactions and nanoscale spatial organisation of proteins. While transcriptomic and proteomic methods have enabled single-cell profiling, scalable technologies allowing high-resolution analysis of protein interactions at omics-scale are lacking. Here we present the Proximity Network Assay (PNA), a DNA-based method for constructing three-dimensional nanoscale maps of 155 proteins in single cells without the use of optics. PNA employs barcoded antibodies and in situ rolling circle amplification to generate >40,000 spatial nodes per cell, which are linked through proximity-dependent gap-fill ligation and decoded by DNA sequencing, forming single cell Proximity Networks. At an estimated spatial resolution of ∼50 nm, PNA captures single-cell protein abundance, self-clustering, and colocalization, validating established cell membrane protein interactions. We illustrate how PNA can be used to gain insights into the molecular mechanisms of cell function through protein interactions in hematological oncology, CAR-T cell therapies, and autoimmune disease.
Open AccessSingle-Cell Protein Interactomes by the Proximity Network Assay
Cellular function depends on dynamic interactions and nanoscale spatial organisation of proteins. While transcriptomic and proteomic methods have enabled single-cell profiling, scalable technologies allowing high-resolution analysis of protein interactions at omics-scale are lacking. Here we present the Proximity Network Assay (PNA), a DNA-based method for constructing three-dimensional nanoscale maps of 155 proteins in single cells without the use of optics. PNA employs barcoded antibodies and in situ rolling circle amplification to generate >40,000 spatial nodes per cell, which are linked through proximity-dependent gap-fill ligation and decoded by DNA sequencing, forming single cell Proximity Networks. At an estimated spatial resolution of ∼50 nm, PNA captures single-cell protein abundance, self-clustering, and colocalization, validating established cell membrane protein interactions. We illustrate how PNA can be used to gain insights into the molecular mechanisms of cell function through protein interactions in hematological oncology, CAR-T cell therapies, and autoimmune disease.
- Open Access
- 8 May 2024
- Published by Springer Nature in Nature Methods
- Vol. 21 (6) , 1044-1052
Molecular pixelation: spatial proteomics of single cells by sequencing
The spatial distribution of cell surface proteins governs vital processes of the immune system such as intercellular communication and mobility. However, fluorescence microscopy has limited scalability in the multiplexing and throughput needed to drive spatial proteomics discoveries at subcellular level. We present Molecular Pixelation (MPX), an optics-free, DNA sequence-based method for spatial proteomics of single cells using antibody–oligonucleotide conjugates (AOCs) and DNA-based, nanometer-sized molecular pixels. The relative locations of AOCs are inferred by sequentially associating them into local neighborhoods using the sequence-unique DNA pixels, forming >1,000 spatially connected zones per cell in 3D. For each single cell, DNA-sequencing reads are computationally arranged into spatial proteomics networks for 76 proteins. By studying immune cell dynamics using spatial statistics on graph representations of the data, we identify known and new patterns of spatial organization of proteins on chemokine-stimulated T cells, highlighting the potential of MPX in defining cell states by the spatial arrangement of proteins.
- 8 May 2024
- Published by Springer Nature in Nature Methods
- Vol. 21 (6) , 1044-1052
Open AccessMolecular pixelation: spatial proteomics of single cells by sequencing
The spatial distribution of cell surface proteins governs vital processes of the immune system such as intercellular communication and mobility. However, fluorescence microscopy has limited scalability in the multiplexing and throughput needed to drive spatial proteomics discoveries at subcellular level. We present Molecular Pixelation (MPX), an optics-free, DNA sequence-based method for spatial proteomics of single cells using antibody–oligonucleotide conjugates (AOCs) and DNA-based, nanometer-sized molecular pixels. The relative locations of AOCs are inferred by sequentially associating them into local neighborhoods using the sequence-unique DNA pixels, forming >1,000 spatially connected zones per cell in 3D. For each single cell, DNA-sequencing reads are computationally arranged into spatial proteomics networks for 76 proteins. By studying immune cell dynamics using spatial statistics on graph representations of the data, we identify known and new patterns of spatial organization of proteins on chemokine-stimulated T cells, highlighting the potential of MPX in defining cell states by the spatial arrangement of proteins.
- Open Access
- 24 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue
Somatic copy number alterations (SCNAs) are pervasive in advanced human cancers, but their prevalence and spatial distribution in early-stage, localized tumors and their surrounding normal tissues are poorly characterized. Here, we perform multi-region, single-cell DNA sequencing to characterize the SCNA landscape across tumor-rich and normal tissue in two male patients with localized prostate cancer. We identify two distinct karyotypes: ‘pseudo-diploid’ cells harboring few SCNAs and highly aneuploid cells. Pseudo-diploid cells form numerous small-sized subclones ranging from highly spatially localized to broadly spread subclones. In contrast, aneuploid cells do not form subclones and are detected throughout the prostate, including normal tissue regions. Highly localized pseudo-diploid subclones are confined within tumor-rich regions and carry deletions in multiple tumor-suppressor genes. Our study reveals that SCNAs are widespread in normal and tumor regions across the prostate in localized prostate cancer patients and suggests that a subset of pseudo-diploid cells drive tumorigenesis in the aging prostate.
- 24 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessHigh clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue
Somatic copy number alterations (SCNAs) are pervasive in advanced human cancers, but their prevalence and spatial distribution in early-stage, localized tumors and their surrounding normal tissues are poorly characterized. Here, we perform multi-region, single-cell DNA sequencing to characterize the SCNA landscape across tumor-rich and normal tissue in two male patients with localized prostate cancer. We identify two distinct karyotypes: ‘pseudo-diploid’ cells harboring few SCNAs and highly aneuploid cells. Pseudo-diploid cells form numerous small-sized subclones ranging from highly spatially localized to broadly spread subclones. In contrast, aneuploid cells do not form subclones and are detected throughout the prostate, including normal tissue regions. Highly localized pseudo-diploid subclones are confined within tumor-rich regions and carry deletions in multiple tumor-suppressor genes. Our study reveals that SCNAs are widespread in normal and tumor regions across the prostate in localized prostate cancer patients and suggests that a subset of pseudo-diploid cells drive tumorigenesis in the aging prostate.
- Open Access
- 24 May 2023
- Published by Springer Nature in Research Square
scCUTseq is a versatile framework for spatially resolved single-cell genomic analyses of intratumor heterogeneity
Chromosomal instability and copy number alterations (CNAs) are pervasive in human cancers. However, the exact timing and mechanism of CNA formation during carcinogenesis remain poorly understood. Here, we describe scCUTseq, an agile and robust workflow for spatially resolved single-cell CNA profiling which could be applied to characterize the CNA landscape in tumor samples. Importantly, scCUTseq could clearly resolve the copy number profiles of different cell lines and was free of cross-contamination, highlighting its specificity. Secondly, we assessed the sensitivity of scCUTseq by determining its ability to detect a 7Mb deletion induced by CRISPR-Cas9 in a small percentage (~3%) of cells transfected with two small guide RNAs (sgRNA) targeting the KMT2A and HYLS1 locus on chr11. In 3.3% of the cells transfected with both sgRNAs, scCUTseq detected a single copy of the exact 7 Mb deletion, in line with the quantification by FISH, highlighting the sensitivity of our method. Lastly, to rule out the artifacts introduced by the MALBAC step, we compared scCUTseq with Acoustic Cell Tagmentation (ACT), another single-cell SCNA profiling method that is based on DNA tagmentation and does not involve a whole genome amplification (WGA) step. Both visual and quantitative comparisons revealed that the genome-wide copy number profiles obtained by either method were highly similar, indicating that the WGA step in scCUTseq does not result in obvious artifact CNA calls. scCUTseq is a versatile and scalable method, which can greatly facilitate the depiction of the single-cell CNA profile in cancers.
- 24 May 2023
- Published by Springer Nature in Research Square
Open AccessscCUTseq is a versatile framework for spatially resolved single-cell genomic analyses of intratumor heterogeneity
Chromosomal instability and copy number alterations (CNAs) are pervasive in human cancers. However, the exact timing and mechanism of CNA formation during carcinogenesis remain poorly understood. Here, we describe scCUTseq, an agile and robust workflow for spatially resolved single-cell CNA profiling which could be applied to characterize the CNA landscape in tumor samples. Importantly, scCUTseq could clearly resolve the copy number profiles of different cell lines and was free of cross-contamination, highlighting its specificity. Secondly, we assessed the sensitivity of scCUTseq by determining its ability to detect a 7Mb deletion induced by CRISPR-Cas9 in a small percentage (~3%) of cells transfected with two small guide RNAs (sgRNA) targeting the KMT2A and HYLS1 locus on chr11. In 3.3% of the cells transfected with both sgRNAs, scCUTseq detected a single copy of the exact 7 Mb deletion, in line with the quantification by FISH, highlighting the sensitivity of our method. Lastly, to rule out the artifacts introduced by the MALBAC step, we compared scCUTseq with Acoustic Cell Tagmentation (ACT), another single-cell SCNA profiling method that is based on DNA tagmentation and does not involve a whole genome amplification (WGA) step. Both visual and quantitative comparisons revealed that the genome-wide copy number profiles obtained by either method were highly similar, indicating that the WGA step in scCUTseq does not result in obvious artifact CNA calls. scCUTseq is a versatile and scalable method, which can greatly facilitate the depiction of the single-cell CNA profile in cancers.
- Open Access
- 11 February 2022
- Published by Springer Nature in Research Square
Comparative genomic profiling identifies targetable brain metastasis drivers in non-small cell lung cancer
Brain metastases (BM) severely impact the prognosis and quality of life of patients with non-small cell lung cancer (NSCLC). To identify targetable drivers of NSCLC-BM, we profiled somatic copy number alterations (SCNAs) in 51 matched pairs of primary NSCLC and BM samples from 33 patients with lung adenocarcinoma (LUAD) and 18 patients with lung squamous cell carcinoma (LUSC). BM consistently had a higher burden of SCNAs compared to the matched primary tumors, and SCNAs were typically homogeneously distributed within BM, as revealed by multi-region SCNA profiling in 15 BM samples, suggesting that BM do not undergo extensive evolution once formed. By comparing focal SCNAs in matched NSCLC-BM pairs, we identified BM driving alterations affecting multiple cancer genes, including several targetable genes such as CDK12, DDR2, ERBB2, and NTRK1, which we validated in an independent cohort of 84 BM samples. We explored the metastatic potential of CDK12 and DDR2 in vitro and in vivo and found that overexpression of either gene alone in murine lung cancer cells causes the induction of key genes involved in epithelial-mesenchymal transition. Finally, we performed whole-exome sequencing of 40 NSCLC-BM pairs and identified BM driver mutations in multiple cancer genes, including several genes involved in epigenome editing and 3D genome organization, such as EP300, CTCF, and STAG2, which we validated by targeted sequencing of an independent cohort of 115 BM samples. Our study represents the most comprehensive genomic characterization of LUAD and LUSC BM available to date, uncovering potentially targetable NSCLC-BM drivers and inspiring the design of novel precision treatment strategies for NSCLC patients.
- 11 February 2022
- Published by Springer Nature in Research Square
Open AccessComparative genomic profiling identifies targetable brain metastasis drivers in non-small cell lung cancer
Brain metastases (BM) severely impact the prognosis and quality of life of patients with non-small cell lung cancer (NSCLC). To identify targetable drivers of NSCLC-BM, we profiled somatic copy number alterations (SCNAs) in 51 matched pairs of primary NSCLC and BM samples from 33 patients with lung adenocarcinoma (LUAD) and 18 patients with lung squamous cell carcinoma (LUSC). BM consistently had a higher burden of SCNAs compared to the matched primary tumors, and SCNAs were typically homogeneously distributed within BM, as revealed by multi-region SCNA profiling in 15 BM samples, suggesting that BM do not undergo extensive evolution once formed. By comparing focal SCNAs in matched NSCLC-BM pairs, we identified BM driving alterations affecting multiple cancer genes, including several targetable genes such as CDK12, DDR2, ERBB2, and NTRK1, which we validated in an independent cohort of 84 BM samples. We explored the metastatic potential of CDK12 and DDR2 in vitro and in vivo and found that overexpression of either gene alone in murine lung cancer cells causes the induction of key genes involved in epithelial-mesenchymal transition. Finally, we performed whole-exome sequencing of 40 NSCLC-BM pairs and identified BM driver mutations in multiple cancer genes, including several genes involved in epigenome editing and 3D genome organization, such as EP300, CTCF, and STAG2, which we validated by targeted sequencing of an independent cohort of 115 BM samples. Our study represents the most comprehensive genomic characterization of LUAD and LUSC BM available to date, uncovering potentially targetable NSCLC-BM drivers and inspiring the design of novel precision treatment strategies for NSCLC patients.
- Open Access
- 19 November 2021
- Published by Springer Nature in npj Breast Cancer
- Vol. 7 (1) , 1-11
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Emerging data indicate that genomic alterations can shape immune cell composition in early breast cancer. However, there is a need for complementary imaging and sequencing methods for the quantitative assessment of combined somatic copy number alteration (SCNA) and immune profiling in pathological samples. Here, we tested the feasibility of three approaches—CUTseq, for high-throughput low-input SCNA profiling, multiplexed fluorescent immunohistochemistry (mfIHC) and digital-image analysis (DIA) for quantitative immuno-profiling- in archival formalin-fixed paraffin-embedded (FFPE) tissue samples from patients enrolled in the randomized SBG-2004-1 phase II trial. CUTseq was able to reproducibly identify amplification and deletion events with a resolution of 100 kb using only 6 ng of DNA extracted from FFPE tissue and pooling together 77 samples into the same sequencing library. In the same samples, mfIHC revealed that CD4 + T-cells and CD68 + macrophages were the most abundant immune cells and they mostly expressed PD-L1 and PD-1. Combined analysis showed that the SCNA burden was inversely associated with lymphocytic infiltration. Our results set the basis for further applications of CUTseq, mfIHC and DIA to larger cohorts of early breast cancer patients.
- 19 November 2021
- Published by Springer Nature in npj Breast Cancer
- Vol. 7 (1) , 1-11
Open AccessInterplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Emerging data indicate that genomic alterations can shape immune cell composition in early breast cancer. However, there is a need for complementary imaging and sequencing methods for the quantitative assessment of combined somatic copy number alteration (SCNA) and immune profiling in pathological samples. Here, we tested the feasibility of three approaches—CUTseq, for high-throughput low-input SCNA profiling, multiplexed fluorescent immunohistochemistry (mfIHC) and digital-image analysis (DIA) for quantitative immuno-profiling- in archival formalin-fixed paraffin-embedded (FFPE) tissue samples from patients enrolled in the randomized SBG-2004-1 phase II trial. CUTseq was able to reproducibly identify amplification and deletion events with a resolution of 100 kb using only 6 ng of DNA extracted from FFPE tissue and pooling together 77 samples into the same sequencing library. In the same samples, mfIHC revealed that CD4 + T-cells and CD68 + macrophages were the most abundant immune cells and they mostly expressed PD-L1 and PD-1. Combined analysis showed that the SCNA burden was inversely associated with lymphocytic infiltration. Our results set the basis for further applications of CUTseq, mfIHC and DIA to larger cohorts of early breast cancer patients.
- Open Access
- 9 July 2021
- Published by Springer Nature in Research Square
COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow—COVseq—which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmarked COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrated the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis showed that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.
- 9 July 2021
- Published by Springer Nature in Research Square
Open AccessCOVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow—COVseq—which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmarked COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrated the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis showed that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.
- Open Access
- 23 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-10
COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow—COVseq—which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmark COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrates the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis shows that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.
- 23 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-10
Open AccessCOVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow—COVseq—which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmark COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrates the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis shows that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.
- Open Access
- 26 May 2021
- Published by Springer Nature in Research Square
COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow—COVseq—which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmarked COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrated the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis showed that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.
- 26 May 2021
- Published by Springer Nature in Research Square
Open AccessCOVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow—COVseq—which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmarked COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrated the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis showed that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.
- Open Access
- 5 February 2021
- Published by Springer Nature in Research Square
COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
Genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the spread and evolution of the virus across different populations, geographical regions and species. Here, we present a streamlined workflow—COVseq—based on the CUTseq method that we previously described, which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms, from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We validated COVseq on RNA extracted from the supernatant of a SARS-CoV-2 culture as well as from 85 left-over samples from nasopharyngeal swabs, demonstrating the ability of COVseq to achieve almost complete genome coverage, including the S region encoding the spike protein. A cost analysis showed that COVseq could be used to sequence thousands of samples per week at less than 20 USD per sample. COVseq is a versatile and scalable method that can be readily applied for genomic surveillance of the ongoing pandemic and easily adapted to other pathogens such as influenza viruses.
- 5 February 2021
- Published by Springer Nature in Research Square
Open AccessCOVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
Genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the spread and evolution of the virus across different populations, geographical regions and species. Here, we present a streamlined workflow—COVseq—based on the CUTseq method that we previously described, which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms, from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We validated COVseq on RNA extracted from the supernatant of a SARS-CoV-2 culture as well as from 85 left-over samples from nasopharyngeal swabs, demonstrating the ability of COVseq to achieve almost complete genome coverage, including the S region encoding the spike protein. A cost analysis showed that COVseq could be used to sequence thousands of samples per week at less than 20 USD per sample. COVseq is a versatile and scalable method that can be readily applied for genomic surveillance of the ongoing pandemic and easily adapted to other pathogens such as influenza viruses.